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”Any classification system is only as good as 
 the existing methodology in determining the extent of the local tumour.” 
Donald G. Skinner 
 
I. Introduction 
In clinical pathology, the main aim of a tumour examination is to obtain 
information for the further treatment of the patient and to determine its prognosis. The 
tumour stage and histological type are the most important histopathological parameters 
and they provide the basis for a comparison of data obtain for different centers and for the 
creation of homogeneous patient cohorts to be used for therapy development. Historically 
tumour staging and efforts to achieve uniform histological classification commenced half 
a century ago [1]. The relevant literature is growing and it is continuously being 
restructured. Consecutive staging and histological classification systems exhibit 
significant differences, and appear quite unstable for the practising physician. These 
constant changes seem to endanger comparability over consecutive classifications, as well 
as the formation of homogeneous patient cohorts of high case numbers. It is also open to 
question as to whether these constantly updated classifications constitute a developmental 
process, or are only reorganisations of knowledge necessitated by the most recent 
information. To date it seems that there is no clear answer to this question in the available 
literature. 
The basis of pathological staging is the TNM system created by the joint effort of 
the Union Internationale Contre le Cancer (UICC) and the American Joint Committee on 
Cancer (AJCC). It is in practice modified every five years on average, and so far (i.e. 
since 1968) it has been altered seven times. It should be kept in mind that, although 
categories T, N and M have identical definitions in each edition (e.g. pT1, pT3a, N2), 
their meaning and content have often changed, shifted, been separated or merged, thus 
causing significant uncertainty in clinical practice. For example, pN2 in kidney cancer 
originally meant the localisation of lymph nodes involved, then their number and a few 
years later their size.  
The standards in histological classification are set by the World Health 
Organisation (WHO), and are disseminated in the publications known in pathology as the 
“Blue Books”. The individual tumour types are described in increasing details, which 
helps to enhance the precision of pathological diagnostics. It has become evident from 
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these volumes that the primary driving force behind the renewal of histological 
classifications is recognition of different entities using ever newer methods. As a 
consequence, once again there is significant variation; however, the results of the use of 
an increasingly precise nomenclature are also evident even today. For example, 
sarcomatous kidney cancer, formerly an independent entity now means the 
undifferentiated forms of all types. 
At the time of a decision regarding therapy or the introduction of new therapeutic 
procedures, it is well worth checking on the stability of the stage classification and 
histological subtype of the organ in question. If the classification (or some part of it) of a 
given organ is frequently changed, it is worth asking why this happens. One might ask, 
for instance, to what extent the frequent changes are due to statistical uncertainties or to 
methodical inadequacies. 
II.              Objectives 
Our objective was to study the development of the two most important 
pathological factors required for the treatment of urological tumours, namely staging and 
histological typing, in order to obtain data to help devise more accurate procedures. We 
wished to identify those points where their application in daily diagnostic practice is the 
most problematic. Based on our knowledge investigations, two such areas were analysed 
in depth, 
1. We wished to reduce the subjective component present in the pathological staging 
of radical cystectomies, and to this end we developed a cut-up protocol that 
minimises it. 
2. We wished to examine the applicability of the genetically based classification of 
kidney tumours in the differential diagnostics of papillary kidney tumours.  
III.   Evolution of the staging system 
III/1 General characteristics of the TNM system for urological tumours 
In general, stages should take into account the anatomical dimensions of primary 
tumours, the status of lymph nodes and distant metastases. The objective of any 
staging system is to help clinicians in planning therapy and to obtain prognostic data, 
as well as to promote the improvement of therapeutic procedures and to permit the 
comparison of data originating from various treatment centres on a uniform basis. 
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In 1954 the Union Internationale Contre le Cancer (UICC) established the 
Committee on Clinical Stage Classification and Applied Statistics, led by Dr. P. Denoix. 
The Committee formulated its recommendations for 23 organs by 1968. These 
recommendations constituted the basis of the first edition of TNM, which, however, did 
not include urological malignancies except for those of the penis. The second edition 
published in 1974, however, was already complete. In the first three editions, there were 
significant differences between preoperative (clinical) and postsurgical pathological 
stages. The latter was a considerably simplified version of the former, and also contained 
numerous inconsistencies. In the case of bladder tumours, for example, the preoperative 
classification of the second edition took microscopic evidence into account. Although this 
can be carried out using a TUR (Trans Urethral Resection) sample, the microscopic 
diagnosis of uterine or vaginal involvement, which is required for staging as pT4a, is 
surely infeasible. Cystectomy may be presumed, which, however, is a postoperative state 
in any case. At the same time, pathological stages themselves do not contain subgroups, 
which are often assessed by microscopic examination. However the separation of a 
pathological staging system from clinical ones gradually occurred.  
III/2 Kidney tumour  
The first staging system was created by Flock and Kadesky in 1958, based on 
macroscopic surgical and pathological observations. However, a five-year follow-up of 
353 cases did not reveal any significant differences between stage 1 and stage 2 [2]. In 
1963 Robson improved the system, which became widely accepted after. In the course of 
the surgical and pathological evaluation of 88 operations including lymphadenectomy, 
Robson established that prognosis depended on histological grade, the infiltration of the 
macroscopically visible veins; the involvement of the surrounding structures the presence 
of metastases in lymph nodes and distant organs (Table 1).  
Stadium Description 
I Tumour is confined to the kidney. Perinephric fat, renal vein and regional nodes show 
no evidence of cancer. 
II Tumour involves the perinephric fat, but is confined within the Gerota’s fascia. Renal 
vein and regional nodes show no evidence of cancer. 
III The tumour involves the renal vein or regional nodes with or without involvement of 
vena cava or perinephric fat.  
IV Distant metastasis secondary to renal cell carcinoma present on admission. Or, 
histologic involvement of visceral structures by tumour.    
Table 1. Robson’s tumour stage classification system 
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Robson’s classification allowed a more precisely classified than with former 
systems. However, just four categories were available, hindering the possibility of a more 
precise differentiation. Despite this, it was more widely used at that time than the first 
three TNM systems. 
The first TNM classification did not include the kidney. The second considered 
the postoperative pathological stage to be identical with the preoperative clinical stage, 
even though the vascular propagation of the parenchyma or arteriographically verifiable 
parenchyma continuity cannot be subjected to a histological analysis. Similarly, lymph 
node fixation in the N3 category can only be assessed surgically. The M category was not 
included in the second edition. The involvement of the neighbouring organ was classified 
as the T4 category in the second edition. This was far seeing in the case of the adrenal 
gland, whereas it was treated as a lower category in next four editions and returned to its 
former position only in the most recent editions. The third edition included a separate 
stage defined “V” category that indicated vascular involvement, which appears to have 
been influenced by Robson’s classification (Table 2). 
Table 2.  The third edition of TNM included a separate “V” category that indicated 
vascular involvement 
Categories based on tumour size were first introduced in the third edition. A low 
size range was reserved for T1 stage, just for incidentally recognised tumours. As regards 
lymph nodes, the stage-determining role of laterality was withdrawn and classification 
was based not just on the size but also the number of nodes. The M stage was introduced 
and it has remained unaltered to this day. The fourth edition abolished “V” category and, 
following the general TNM concept, merged it into the T category. This also meant an 
integration of the Robson system into the TNM nomenclature. At that time subcategories 
were introduced, opening up the possibility of a more refined classification. The 
involvement of the adrenal glands was still not clarified, but it was treated as a lower 
stage (T3a) than in the second edition. The fifth edition introduced a tumour diameter of 7 
cm as the cut-off between the T1 and T2 categories, which has, been retained. The N3 
category was abolished and the rest was left unchanged. In the sixth edition, tumours with 
V0 Veins do not contain a tumour 
V1 Renal vein contains a tumour 
V2 Vena cava contains a tumour 
VX Veins cannot be assessed  
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diameters less than 7 cm were classified into subgroups. In the seventh edition, tumours 
larger than 7 cm were also divided into subgroups, and a tumour spreading to the adrenal 
gland in a continuous fashion was classified as pT4.   
III/3 Bladder tumours 
The foundations of the stage classification of bladder cancers were laid down by 
Jewett and Strong [3]. Between 1919 and 1944, they analysed the autopsies of 127 
patients who died as a consequence of infiltrating tumours. They found a correlation 
among metastasizing tumours, a spread in lymphatic vessels, fixation to surrounding 
structures and tumour infiltration depth. Three groups were defined, namely A: 
submucosal infiltration, B: muscular infiltration, and C: perivesical fixation (Figure 1). 
They showed that the number of lymph nodes involved and the probability of distant 
metastases and of fixation increase with muscular infiltration and that these are even 
higher when extra organic propagation occurs. They found that submucosal spread is 
potentially curable, whereas only a quarter of fixed tumours are successfully treated. This 
publication clarified the position of the efferent lymphatic vessels of the bladder relative 
to the peritoneum and the abdominal wall, and identified the organs that most often 
harbour distant metastases (non regional lymph nodes, liver, lungs, vertebral column) [3]. 
 
In 1952, based on 80 cases, Jewett further refined this classification system: he 
divided muscular involvement into B1 (superficially invasive) and B2 (deeply invasive) 
groups [4]. The soundness of this decision is still being debated, and Jewett himself had 
doubts at one point. In fact, in 1978, he wrote: “It seems probable that our arbitrary 
dividing line drawn 30 years ago at the halfway level to separate B1 (pT2a) from B2 
(pT2b) tumours was too superficial” [5]. Nevertheless, the division is still valid today. 
The work of Jewett and Strong was supplemented by Marshall, who introduced stage 0 
and in situ carcinoma, and separated tumours not infiltrating the lamina propria. 
However, he also included those cases where the presence of neoplasia was confirmed in 
Figure 1. The stage 
classification by Jewett and 





a biopsy within 30 days, even though it was not observed at the time of the examination 
[6]. 
The classification proposed by Jewett, Strong and Marshall was largely 
incorporated into the TNM system. It translated the letter symbols into its own 
nomenclature, and supplemented the pathological classification with a clinical 
interpretation. The entity known today as pTa corresponds to pTis in the second edition; it 
is not mentioned in the third edition, and is again in continuous use starting from the 
fourth edition. Consequently, it is from that point on that the meaning of pTis as a “flat” 
tumour can be considered well established. Actually there were no more modifications at 
thet point in the later and third editions. Subepithelial connective tissue infiltration, once 
separated by Jewett, is still in use under the name of pT1. In the fourth edition, perivesical 
adipose tissue infiltration was first divided into microscopic and macroscopic categories. 
In the case of lymph nodes, the size of the metastasis has become relevant, like in other 
organs. The fifth edition has the classification used today, the only difference being the 
consideration of the number and localisation of the lymph nodes involved.  
III/4 Accurate determination of the pathological stage of radical cystectomy 
specimens using an oriented cut-up protocol  
 
The stages assessed in cystectomy reveals a considerable variability in the 
publications [7-21] (Table 3). We think that, behind this heterogeneity there is an 
insufficient standardisation of the pathological processing of radical cystectomy 
specimens. As regards the importance of the pathological reports [22, 23], a Gross 
Dissection Protocol for Radical Cystectomy (GDPRC) samples was developed and 
introduced into the daily routine practice of our Institute. Our main intention was to 
further improve the European recommendation [24] by utilising the potential of the 




Table 3. 15,586 stage related data taken from more than 27, 397 cystectomies, 
reported in 15 international publications. Here, we focused on credibility. Only those 
papers were considered which presented more than 350 cases, demonstrated the practice, 
and all of the stages were described including pT0 
 
The incidence of tumours of the bladder has been on the increase over the past 
two decades, and this type of tumour is a problem of increasing importance world-wide. 
In 2002, 357,000 new cases were registered globally by the WHO, making bladder cancer 
the fifth most common tumour type in men and the eighth in women [25]. The treatment 
for advanced bladder tumours (pT2–4a) is radical cystectomy. In Hungary, for instance, 
172 operations of this type were performed in 2010.  
 The most important information for clinical decisions regarding advanced bladder 
cancer and for the determination of its prognosis is the clinical stage of the tumour. The 
majority of these tumours are of urothelial origin and are poorly differentiated, which 
means that they cannot be classified on the basis of these characteristics [22]. In nearly 
half of the cases, the clinical stage does not match the post-surgical classification based 
on histopathological examination [26] because physical examination and imaging 
techniques are of limited value for the establishment of the clinical stage. The typical 
accuracy of CT scans is only 54.9%. In 39% of the cases it gives larger dimensions and in 
6.1% of the cases gives smaller dimensions than those confirmed by histology [27]; and, 
similarly, CT is not adequate for the evaluation of either muscle invasion [28] or  spread 
to the perivesical areas and into the lymph nodes [29]. Recent technical innovations have 
not improved this situation. Neither has the application of fluoro-2-deoxyglucose PET/CT 
significantly enhanced the precision [30]. Overall, clinical and pathological stages 
coincide only in about one-third of the cases [31]. It has been established that the 
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pathological examination is decisive for the design of postoperative therapy and for 
prognosis [16, 22, 23]. The most important step of the pathological processing of the 
sample to be studied is the selection of the areas to be processed for microscopic 
examination, because these areas will represent the entire tumour, and these will be 
studied in detail by microscopy, immunhistochemistry or pathological consultation.  
 Microscopic examinations go back much further than the guidelines for the cut-up 
of surgical samples. Consequently, their system of criteria is not as developed as that of 
the latter. The first set of guidelines regarding the cut-up out of a urinary bladder that was 
removed because of cancer was issued 55 years ago [32]. Several manuals of ever 
improving quality were published before the latest one considered which is to represent 
the standard technique [24]. All of these recommendations are consistent in that they 
enumerate the areas of the specimens that need to be cut out, but do not elaborate on the 
mode of cut-up, even though they describe two different procedures for the dissection of 
the specimen in detail. The mode of cut-up and the positioning in microscopic sections of 
certain organs such as the uterus, the cervix, the fallopian tube, the appendix and the skin 
have been meticulously regulated. The main objective of all these guidelines is to reduce 
the subjectivity in the cut-up procedure that come from the different detections of the 
pathologist. 
 Here we describe in detail the cut-up, embedding and microscopic evaluation 
steps of the processing of radical cystectomy samples as well as the results obtained, and 
we will also mention the financial and workload aspects of the procedure. 
From 2008 to the first quarter of 2012, 138 radical cystectomies were performed at 
the Department of Urology of the University of Szeged. These samples were 
histologically processed as a whole using macroblocks. They were taken from 99 men 
and 39 women. The average age was 62.3 years; that of men was 64 years (range: 41-76), 
whereas that of women was 60.6 years (range: 49-71). 
Processing of surgical samples 
The processing and histological evaluation of cystectomy specimens is described 
in the publication [33]. In short, the samples were fixed in 10% formalin without 
dissection, for a minimum of three days. The cut-up procedure of the cystectomy material 
is schematically presented in Fig. 2. An anterior orientational incision was made from the 
urethral orifice to the bladder dome (Fig. 2). Male and female bladders were further 





Figure 2. The cut-up procedure of radical cystectomy (a: male b: female)  
 
Cut-up steps of the male urinary bladder 
1. The preparation of an urethral resection line   
2. A wedge-shaped section of the prostate  
3. The preparation of a bladder-prostate basal block including the bladder 
base and the prostate base  
4. The preparation of 12 radial sections of the basal block  
5. The preparation of cross-sections above the basal block  
6. The processing of the bladder dome in sagittal parallel levels  
7. The embedding of the seminal vesicle. 
Cut-up steps of the female urinary bladder 
1. The uterus complete with its bilateral appendages and the antero-superior 
area of the vaginal wall were separated from the bladder  
2. A cross-section also containing the urethral resection level was prepared 
for further study. 
3. The bladder was embedded in the form of cross-sections. 
4. The processing of the bladder dome was identical with the cut-up steps of 
the male bladder. 
5. The uterine portio and the vaginal stump were embedded in parallel 
sections after separation from the cervix.    
6. The entire area of the uterine cervix in contact with the urinary bladder 
below the peritoneal junction was embedded in cross-sections.  
7. The uterine corpus and the bilateral appendages were prepared for 
examination using the relevant procedural protocol [34]. 
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 The GDPRC was implemented in a non-rigorous way. The most frequent 
modification was that of visualisation, for both cutting levels, of the lesion selected as 
important on the cutting surface. Regional lymph nodes were embedded as a whole and 
larger ones were halved. 
 Stages were determined with the AJCC/UICC TNM system, which was revised in 
2002 [23]. The frequencies of the individual stages were then expressed in percentages.  
Differences were evaluated using the one-sample z-test. (p value<0.05)  
 The data on stages and sizes 
The GDPRC was introduced as a daily routine processing procedure at the 
Institute of Pathology of the University of Szeged in 2008 and, in the case of each radical 
cystectomy specimen, it has been maintained ever since.  
The results are shown in Table 4. Obturator lymph nodes were removed in 126 cases 




pT0 pTa pTis pT1 pT2 pT3 pT4 
No. of cases  (%) 12 (8.7) 1 (0.7) 4 (2.9) 21 (15.2) 29 (21) 48 (34.8) 23 (16.7) 
Total no. of lymph nodes 240 13 64 398 517 840 327 
Average no. of lymph nodes 20 13 16 21 39.4 39 29.5 
No. of metastatic lymph nodes 
(percentage of total no. of lymph 
nodes in category) 
13 (5.4) 0 0 2 (0.5) 18 (3.4) 123 (14.7) 58 (17.7) 
 
Table 4. The stage distribution in 138 consecutive radical cystectomy assessments 
with the GDPRC   
The average sizes of the 124 preparations were: supero-inferior 101.6 mm (range: 
40-170); medio-lateral 92.7 mm (range: 40-140); antero-posterior 75.7 mm (range:35- 
130). The average mass of the 119 specimens was 308 g (range: 46-680). 
Using the macroblock technique, we were able to prepare 7-mm-thick bladder 
wall sections and prostate sections with a maximal thickness of 5 mm. 
Material consumption and costs  
On average, 9.2 macroblocks and 14 standard blocks were used for our processing 
of the bladder and the prostate. In the case of radical cystectomy of male patients, an 
average of 9.8 macroblocks and 16.3 standard blocks were prepared. In the case of 
cystectomy of female patients, 8.8 macroblocks and 9.6 standard blocks were applied. 
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The cost of the materials used for preparation of a macrosection was €1.8, whereas 
that of a standard histological section was €0.25. The average cost of the materials and 
chemicals used for processing using to the GDPRC of a male radical cystectomy 
specimen was €21.8 and that of a female one, €18.2. A necessary one-time investment 
was that of a macro head for the microtome. Cut-ups with photographic documentation 
took about two hours per case and the microscopic examination took further two hours of 
the pathologist’s time. 
 The cut-up procedure of the urinary bladder has remained basically unchanged 
since the publication of the first guidelines 55 years ago; it has only been supplemented 
by a list of the anatomical structures deemed important to examine. These guidelines 
leave it to the pathologists to select those of the listed areas that may be expected to 
contain microscopic lesions [24]. This method of selection, however, is only of limited 
value, especially in the case of formalin-fixed samples [35]. Due to the recognition of the 
significance of the additional information to be gained for clinical use, the need for a 
more precise determination of the pathological processing technique of cystectomy 
specimens arose fifteen years ago [36]. The first trial with a relatively large case number 
was conducted by Soto et al. They inflated the bladder with celluloid, and applied a 
lengthy procedure only to 45 radical cystectomy preparations that could be examined as a 
whole over the fifteen-year period [35]. The most commonly applied method is the step-
sectioning, which begins with the urinary bladder being opened through the urethra by a 
cut along the anterior wall, stretched on a corkboard and fixed. The bladder and the 
connected organs are next cut into 5–10 mm horizontal sections, which are embedded in a 
topographically registered block. The overview of the often very numerous microscopic 
sections of course necessitates graphic registration. A similar technique is one that has 
been the only method recommended for application as a routine evaluation procedure, in 
which the sample by an incomplete frontal and a subsequent sagittal cut results in a 
specimen consisting of four quadrants forming an X shape. The 50–100 blocks per case 
were grouped by quadrants, marked by the letters of the alphabet and located on a 
photograph or drawing of a specimen [36]. However, the reconstruction with standard 
blocks and the dimensions of the tumour cannot be accurately determined due to the 
distortion of size and the difficulties of orientation. In addition, it is not suitable for the 
examination of relatively large tumours prolapsing into the lumen, because these cannot 
be laid out without destroying them. Owing to this, the same is true for the cut-up 
guidelines currently in use. All in all, the step-sectioning method may only address one or 
two special targeted questions for research purposes. Dissection in a single sagittal 
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section led medially through the specimen may be demonstrative and it is used in 
textbooks and publications to support the conclusions they have reached.  
Today, the accepted routine pathological processing of cystoprostatectomy 
samples is summed up in the pathological handbook edited by Rosai and Ackerman. This 
manual represents the most widely accepted international recommendations. It provides a 
list containing the anatomical locations to be examined, and two drawings to aid 
dissection; the latter also show some of the locations to be examined, given in the list. 
When only minimal cut-ups are considered, at least 25 have to be made on a male 
bladder, and only three (!) of these will come from the tumour [37].  
With the GDPRC we perform the examination on macrosections in a standardized 
mode which eliminates subjectivity inherent with the cut-up procedure described above. 
This is the most critical step of pathological processing and we adapted it to the 
conditions of daily routine, while keeping the possibility of intervention open. Obvious 
advantages of the GDPRC are the following: 
This technology allows an unambiguous definition of category pT0 
 Values between 6% and 41% proportion of pT0 resections have been reported as 
not negligible [16, 38]. What is more, due to the increasingly effective neoadjuvant 
therapies and the application of extended TURB, an increase in the number of cases is 
expected [39]. In the absence of suspicious macroscopic signs or data regarding the 
localisation of earlier interventions, there is no guidance on how to preforms the cut-ups. 
If the first cut-ups displaying tumour negativity were made in a non-oriented fashion, 
subsequent cuttings can only be incidental, and no guidance is given for their mode, 
extent or number. The papers investigating the clinical significance of pT0 sought to 
verify tumour negativity by taking random cut-ups [40]. The heterogeneity of 
pathological processing may be a significant factor in the standard deviation of the 
frequency of pT0 of published data. In the course of implementing the GDPRC, only 
those resections were classed as pT0 resections where the granulomatous area and the 
hemosiderin deposition indicative of the earlier intervention were observable and the 
entire preparation appeared tumour-free.  
Subcategories of category pT2 can be precisely determined  
Recently the usefulness of pT2 subcategories has become the focus of intensive 
debate. The division of muscle invasive tumours into internal and external layer 
involvement was based on Jewett’s experience of autopsies of 107 patients who died from 
bladder cancer. The TNM system has also adopted this classification [41]. In contrast, 
Cheng et al. identified tumour size rather than infiltration depth as a prognostic marker, 
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and supported their conclusion with numerous references [42]. In the course of follow-ups  
123 muscle invasive tumours, American researchers failed to find any difference among 
subcategories of various infiltration depths, and hence suggested the simplification of the 
AJCC’s classification based on the same principles; in other words, they abolished 
subcategories [43]. A recent international study, however, found the TNM system feasible, 
based on 565 cases [44]. The settling of the debate is made more difficult by the fact that 
after formalin fixation, aggressively infiltrating tumours exhibiting unicellular and 
tentacular spread which cannot be seen during naked eye examination or by palpation. 
Also, current imaging techniques do not offer any better resolutions than the microscopic 
ones. All these things can be overcome with the GDPRC, where the simultaneous 
preservation of the localisation and dimensions of the infiltrating area as well as its 
relationships with the surrounding tissues of tumour can be tested. 
The category pT3a can be precisely identified.  
The cut-ups for examination of microscopic progression beyond the bladder using 
the naked eye can only be done theoretically. All these circumstances may have 
contributed to the numerous reports of the failure to find differences between pT2 and 
pT3a [45]. The determination of the stage as to whether it is localised to the organ or 
spreading extravesically is also essential for prognosis and the planning of adjuvant 
therapy [46]. The validity of the subcategorisation of stage pT3 has been verified on the 
basis of a large number of cases (n = 2388), and this supports the usefulness of the 
currently used TNM system [45]. The GDPRC enables the identification and localisation 
of extravesical spread and measurement of its dimensions.  
The category pT4a and prostate infiltration can be assessed precisely   
The infiltration of dense prostatic tissue (pT4a) after formalin fixation is usually 
invisible to the naked eye. The route of spreading can occur (i) by breaking through the 
entire thickness of the bladder wall, or (ii) via the urethra. This point has some prognostic 
significance [47]. There is, however, no advice given on the method of the examination of 
prostate infiltration. Donat et al. studied three specimens cut to 3-mm-thick sagittal 
sections [47]. In this way, the urethra can be represented in only one or two cutting 
surfaces, whereas the urethra may not just be a route of infiltration but also a primary 
tumour site. The other possibility is the separation of the bladder and prostate. In this case 
both organs are dissected according to the protocol corresponding to the primary cancer 
of the given organ [48]. Our approach offers the possibility of microscopically studying 
both organs in one section. The 12 radial cut-ups of the bladder-prostate basal block not 
only preserve the relationship between the two organs, but 3D measurements and the 
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circumferential resection distance can also be determined. This is important because it 
concerns the nearest resection edge. Our approach allows an extensive examination of the 
bladder neck as well.  
Processing of prostate and urethra 
The entire prostate tissue below the bladder-prostate basal block was studied in 
macrosections, in compliance with the current recommendation [49]. However, since the 
prostatic urethra runs in an anteriorly open angle, the cross section plane of the urethral 
resection margin and the plane of the basal block are not parallel but form a triangular 
section. (The reason why this does not occur in prostatectomy specimens is that the 
urethral resection line is not taken into account during the preparation of either the apex 
or the base, because it is not our intention to get complete cross-sections of this part.) The 
orifices open antero-medially from the vertical axis due to the physiological anteflexion 
of the urethra. In order to retain all surgical edge markings in the sections, further cuttings 
were also performed at an angle. In the case of prostate tumours, the infero-superior size 
was estimated from the slide thickness as half of the maximal thickness of the triangular 
block. Our approach permits the extensive examination of the bladder neck area, the 
proximal part of the urethra and periurethral tissue. In the case of urethral stump 
involvement, the distance from the resection margin was assessed from sagittal sections 
made after recovery from the block by melting. 
Comparison of the Stage Distribution Assessed by the GDPRC with the Literature  
The incidences of the pathological stages of cystectomies exhibit significant 
differences even within the same geographical region and time interval, even when the 
tests performed prior to cystectomy and the surgical indications are practically identical. 
Nevertheless, the incidence determined on the basis of a large number of cases must 
reflect the actual incidence. We therefore carried out determinations by using the data on 
15,586 stages of 27,394 cystectomies presented in 15 publications from the period 
between 1971 and 2010  [5, 9–22]. Here, we just concentrated on credibility. We 
reviewed those papers that described over 350 cases, demonstrated the practice, and each 
category was present, including pT0. Furthermore, the percentages were also given along 
with numeric data for each category. (Blank spaces are shown where data were combined 
in the table.) We also created a summarised group from each category and counted the 






The relatively small number of cases evaluated with the GDPRC quite accurately 
reflects the statistical data based on a lower number of cases. The differences observed 
are due to our more precise approach: the case numbers in the pTis-pT2 groups were 
smaller, while those in groups pT3 and pT4 were greater. With pT4, the difference was 
significant (11.36 % vs. 16.6 %, p=0.049).We think that the more frequent occurrence of 
cases in the highest stage may provide a partial explanation for the generally bad 
prognosis of cystectomies. 
The incidence of pT0 among the cases we studied was slightly higher than the 
average of the published data (8.7 % vs. 6.1 %). The reason for this may be that the 
histological examination of preoperative TUR cannot provide a reliable evaluation of the 
completeness of tumour removal, and the resolution of imaging techniques is insuffitient  
in cases of small tumours. The surgical indications for this stage are therefore more 
uncertain, and are unsuitable for a good comparison. 
The sample dissected using the GDPRC also allows the evaluation of other possibilities 
The GDPRC allows as a part of daily routine the assessment of further prognostic 
factors such as: 
1. The three-dimensional measurement of tumour dimensions 
2. The representation of the full heterogeneity 
3. The mapping of the infiltration pattern 
4. Microscopic measurement of the distance and the extension of 
the circumferential resection line 
5. The better identification able of vascular and perineural 
infiltrations 
6. The determination of the associated urothelial dysplasia/in situ 
carcinoma.  
Figure 3. Standard deviation of 
15,586 staged cases taken from 
the literature. The values in red 
show the average frequency and 
the values in green show the 
results with the GDPRC. For 





Limitations of the GDPRC 
The GDPRC is more labour intensive and more expensive than the protocols used 
today. Current processing requires cutting into 25 standard cassettes, and this means only 
three standard blocks from the tumour and one from the surrounding mucosa. Hence the 
estimated cost is at least €6.25 (25 x €0.25 = €6.25). The amount of materials used by the 
GDPRC for male bladders is three and a half times more and for female bladders, three 
times more.  
  Macrosection preparation requires a lot of practice, but the majority of the 
technical staff has already gained the necessary experience in the course of processing 
other organs, and they are capable of cutting 4–6 micrometre sections. Staining and the 
immunohistochemical processing of macrosections have not yet been automated. The 
GDPRC is especially labour intensive for pathologists.  
 The 7-mm-thick slides placed in macroblocks using the GDPRC technique as part 
of the routine pathological procedure is a reasonable compromise because we do not need 
to inflate the bladder before fixation, or to submit it to special preparative procedures 
under clinical conditions. 
The GDPRC is not suitable for the processing of atypically resected material.  
In spite of the unparalleled development of diagnostic and therapeutic devices, the 
survival rate of patients undergoing radical cystectomy has not improved in the past forty 
years. Their five-year survival rate continues to be barely more than 50% [50]. In order to 
improve the pathological examination that determines the post-operative therapy, we 
applied macroblock techniques to minimise subjective factors affecting cut-ups in daily 
routine. This may be required not just for the pathological examination and for the 
comparability offered by the rapidly developing imaging procedures, but also for the 
determination of the effectiveness of locally instilled, molecularly targeted therapies, the 
introduction of which is expected in the near future.  
 
III/5  Prostate tumours 
The first prostate staging system was published in 1956 by Whitmore. He devised 
four groups; namely A, incidentally recognised, not palpable; B, palpable and localised to 
the organ; C, spreading outside the prostate but not metastasizing; D, metastatic tumour 
[51]. This system was further refined by Jewett with the introduction of subgroups, 
creating a pathological approach that has a prognostic potential. In the Whitmore–Jewett 
system, also known as the ABCD system, a localised tumour might be focal (A1) or 
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diffuse (A2). In B1, the tumour involved not more than one lobe, whereas in B2, it was 
more, but it did not spread beyond the capsule. C1 stage tumours cause minimal invasion, 
and C2 cause extensive extracapsular, ureteral or urethral obstruction. Due to its ready 
applicability, the Whitmore–Jewett system gained wide use in the United States, but it 
was not appropriate for the description of a more complex process. About 25% of patients 
with a tumour extension corresponding to stage B already have nodal metastases, which 
places them into the D1 category; however, D1 itself contains no information regarding 
the tumour size or extent. Neither did the determination of extension relative to the lobes 
– a subject of continuous debate to this day – permit accurate usage. The demand for 
differentiation in terms of size was already formulated at that time. 
 The first edition of TNM did not include the prostate, or any other urological 
malignancies. The classification given in the second edition was not widely accepted. The 
third edition essentially adopted the Whitmore-Jewett classification, but applying the 
TNM designations (Table 5).  
Table 5. Comparison of the 1978 TNM classification with the Whitmore-Jewett system  
 
In situ prostate carcinoma (pTis) was omitted, and subgroups were introduced. Extension 
became the main parameter, replacing uni- or multifocality. This approach has been 







Description in TNM nomenclature 
 
T0 - No evidence of tumour 
T1a A1 Three or fewer microscopic foci of  carcinoma 
T1b A2 More than three  microscopic foci of  carcinoma 
T2a B1 Tumour 1.5 cm or less in greatest dimension with normal tissue on a 
least three slides 
T2b B1 Tumour more than 1.5 cm in greatest dimension or in more than one 
lobe 
T3 C1 Tumour invades the prostatic apex, or into or beyond the prostatic 
capsule, bladder neck, or seminal vesicle but is not fixed  
T4 C2 Tumour is fixed or invades adjacent structures other than those listed 
in T3 
N0 - No regional lymph node metastasis 
N1 D1 Metastasis in a single lymph node, 2 cm or less at greatest dimension 
N2 D1 Metastasis in a single lymph node more than 2 cm, but not more than 
5 cm at greatest dimension, or in multiple lymph nodes none more 
than 5 cm at greatest dimension 
N3 D1 Metastasis in a lymph node more than 5 cm at greatest dimension MX 
Presence of distant metastasis cannot be assessed 
M0  No distant metastasis 
M1 D2 Distant metastasis 
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subgroups according to the laterality of extracapsular spread. Apex infiltration was 
designated pT2 rather than pT3; however, the bladder neck was placed into the pT4a 
category. Also, nodal stages were classified in terms of size. With the incorporation of 
distant metastases, this classification applied is the same even now.  
The fifth edition of TNM practically meant that the pT1 group was no longer used 
there, but was still used in clinical TNM. Although this stage could only be confirmed by 
histological testing, microscopic examination in itself was not suitable for the 
determination of the stage (anatomical extension). The basic objection was that, due to 
the sampling technique applied, the exclusion of a possible higher stage was impossible. 
In other words, a TUR sample is not suitable for excluding the possibility of 
extraprostatic spread or seminal vesicle involvement.  Although extraprostatic extension 
may be observed in needle biopsies, the involvement of the seminal vesicle cannot be 
wholly excluded. Indeed, the T1c was justified only when tumour spread had also been 
confirmed by a clinical examination, even when it had been revealed in biopsies taken 
from both sides. This practice placed special emphasis on excluding the uncertainty 
introduced by the sampling technique. The identification of the pathological stage 
requires samples from radical prostatectomy and from the lymph nodal regions. 
The fifth edition made an attempt to simplify matters. The involvement of only 
one or both lobes was to be taken into account by the classification into one of two 
subgroups. As will be seen below, this attempt eventually proved unsuccessful. 
A detailed description of pathological stages helps to rule out anomalies such as 
the requirement of fixation to neighbouring structures in the case of the pT4 category. 
Only the criterion of bladder or rectum involvement was retained (inasmuch as it can be 
histologically assessed, i.e. it is contained in the sample). The spread to the bladder neck 
still received no special emphasis, so it was included as part of the pT4 category. 
Moreover, positivity of the surgical margin is mentioned for the first time, although this is 
due to surgical interventions than the physical extent of the tumour.  
In case of tumours localised to the organ, the categories of the fourth classification 
applied ten years earlier were reintroduced in the sixth edition. The simplification that 
wished to take into account only the involvement of one or two lobes provided not to be 
sufficiently prognostic [52].  However, the classification used over nearly a quarter of a 
century and also adopted by the seventh edition is not satisfactory either. It is evident that 
in the case of two small tumour foci, their location on one or two lobes (pT2a vs. pT2c) 
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has no significant impact on prognosis. But a large tumour involving half of a lobe 
probably has a worse prognosis than two small tumours of bilateral localisation, each 
measuring a few millimetres [53]. For this reason the need for classification in terms of 
size had already been recognised previously; however, the satisfactory way for such a 
classification has not yet been identified [54].  
The seventh edition treated bladder neck infiltration separately, and classified it as 
pT3a.  
III/6 Testicular tumours 
Clinical and pathological stages are separated in the TNM system in general, but 
in the case of the testes this is not so explicit. The T categories are identical with two 
exceptions (pTis and pT4). This means that determination of the clinical stage 
necessitates histological examination following orchiectomy. In situ carcinoma can of 
course be examined only by applying histological methods; this category first appeared in 
the third edition of TNM. 
In the fourth edition the significance of the involvement of rete testis as an 
anatomical region of testes diminished, and it was changed from pT2 to pT1. Epididymis 
involvement was moved from pT3 to pT2, funicular involvement from pT4a to pT3, and 
scrotal involvement to pT4. Thus subcategories were eliminated from the TNM system of 
the testicular cancer. As for lymph nodes, classification in terms of size was introduced 
like in other urological tumours and using identical size ranges. 
In the fifth edition, vascular involvement was introduced as a staging factor and its 
presence meant pT2. Distant metastases were divided into two subgroups, namely lymph 
nodes beyond the given region and lung metastases (M1a) and metastases located beyond 
these structures (M1b). Even though it is not a pathological definable stage, the S stage, a 
new concept introduced as an exception to the TNM system based on anatomical 
extension, should also be mentioned. The new category served to confirm the prognostic 
significance of serum marker levels. In a minor modification of pN2, tumour spread 
beyond the lymph node irrespective of extension was also introduced. 
In the sixth and seventh editions, no changes were made concerning the testis, 
which means that the same system has been used for 15 years, thus constituting the most 




III/7 Penile tumours 
The penile staging classification system introduced in 1966 by Jackson was in use 
up to the first TNM classification (Table 6).  Classification in terms of categories was 
based on tumour operability and lymph node status, and did not take size, depth of 
infiltration or histological appearance into account [55]. 
Jackson stage TNM Stage Groups  
Stage I  T1-T2, N0, M0 Tumour limited to glans penis and/or prepuce 
Stage II  T1-T2, N0, M0 Tumour extending onto shaft of penis 
Stage III T1-T3, N1-2, M0 Tumour with malignant but operable inguinal 
nodes 
Stage IV  T1-T4, N0-N4, M0-M1 Tumour invades adjacent structure; inoperable 
nodes or distant metastasis 
Table 6. Comparison of Jackson’s categories with the firstly introduced TNM stages 
As a single exception among urological tumours, penile cancer was already 
included in the first edition, and it was retained in the second and third editions without 
any change [56]. Pathological stage referred to clinical stage without modification. A 
penile tumour was treated as a superficial process by this system, and it was classified in 
terms of extension. Surgeons from Heidelberg worked out a modified TNM system, 
taking into consideration the localisation of the primary tumour and the extent of 
infiltration. The modifications did not result in any significant differences in the survival 
rate [57].   
The fourth edition brought about considerable change. Verrucous carcinoma was 
introduced as the pTa stage, but pTis was also retained. Size as a determinant factor was 
replaced by the layers affected in the course of in-depth spread. The number and 
localisation of lymph nodes were taken into account instead of the infiltration of the 
surrounding structures, and this was not altered up to the sixth edition. 
In the seventh edition, pT1 was divided into two subgroups, taking 
lymphovascular invasion as well as tumour differentiation into account. The meaning of 
T3 was restricted to urethral involvement. The prostate was treated as an “other 
neighboring stucture”. The clinical and pathological statuses of lymph nodes were 
unambiguously separated, and in N3 the spread of metastases beyond the lymph node also 





IV. Changes in the histological classification 
WHO issues the publications known as “Blue Books” for the histological 
classification of tumours in various organs of the body, among them urological tumours. 
The first of these called “Histological Typing of Urinary Bladder Tumours” was 
published in 1973, followed by “Histological Typing of Testis Tumours” in 1977, 
“Histological Typing of Prostate Tumours” in 1980 and “Histological Typing of Kidney 
Tumours” in 1981. They contained short descriptions of the tumours, supplemented with 
large numbers of photomicrographs. Second editions on renal and testicular tumours were 
republished in 1998, on bladder tumours in 1999 and on prostate tumours in 2002. These 
already included immunohistochemical (IHC) photomicrographs. The two most recent  
WHO classifications are called “Pathology and Genetics. Tumours of the Urinary System 
and Male Genital Organs” (2004) and “Tumours of the Urinary System and Male Genital 
Organs” (2016) summarises urological tumours in one volume. The title itself implies that 
tumours are basically diseases of genetic origin. This publication defines tumour types, 
describes their epidemiology, key clinical features, macroscopic characteristics, 
histological and IHC properties, genetic deviations and prognostic and predictive factors. 
Categories are differentiated by applying classical pathological and genetic tests. These 
last two, even physically most extensive books, also contains a description of tumours of 
the penis. 
VI/1 Kidney tumours 
The first description of a kidney tumour was given by Miriel in 1810. Twelve additional 
cases were documented in the fifteen years following. The first classification was 
proposed in 1826 by König, who classified tumours according to their macroscopic 
appearance (fungoid, medullary, cicatrising and adipose). The first series of kidney 
tumours was compiled by Rayer in 1831–1838, and published in his three-volume 
“Treatise on Renal Disease” in 1841. He classified tumours into three groups based on 
their appearance and clinical features, namely (1) non-visible cancer (tumour of 
medullary appearance without kidney enlargement or haematuria); (2) caliceal cancer 
(with nephric pain and haematuria); and (3) cicatrising cancer (often associated with 
haematuria). In the next two decades, kidney tumour research focused on the histological 
approach in order to determine the histological origin of the cancer. When Robin 
described in 1855 that proliferating cells of the tubular epithelium form tumour nodules, 
he assumed that the cancer originated from the renal tubules. This observation was 
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confirmed by Waldeyer in 1867 by autopsy findings [58]. In contrast, in 1883 Grawitz in 
his book entitled “Die entstheungen von Nierentumouren aus Nebennierengewebe” 
described renal cell carcinoma as a hypernephroma, which he thought originated from the 
adrenal gland due to its histological appearance [59]. In spite of the opinions of leading 
pathologists of the 20th century, this theory and the name “Grawitz tumour” or 
“hypernephroma” have survived and occasionally appear even in present-day publications 
[60]. 
WHO classification of 1981: International Histological Classification of Kidney 
Tumours  
This is the first international consensus classification that takes into consideration 
the microscopic appearance of the tumour, tumour cells and the histological pattern. 
Tumours were divided into benign and malignant tumours, but the main criterion of 
maligancy was a tumour diameter in excess of 3 cm. Malignant tumours were designated 
adenocarcinoma or renal cell carcinoma. It was already known at that time that certain 
morphological types are associated with a more favourable prognosis. In the absence of 
adequate clinicopathological correlation, however, these were not accepted as 
independent entities. Hence, the only categories were adenoma, renal cell carcinoma and 
“others”.  
 
The Mainz Classification (1986) 
For many years, renal cell carcinoma was considered to be a single pathological 
entity, and was subdivided into clear, granular and mixed cell variants. The granular cell 
variant with a predominantly papillary appearance was classified as papillary renal 
carcinoma. In 1976, Klein and Valensi described oncocytoma with a granular cell type 
appearance, an entity with excellent prognosis [61]. Its multiplex form was also described 
later [62] (Figure 4).  
 
Figure 4. Kidney oncocytomatosis. The right 
kidney is occupied by a mass of oncocytomas 
causing renal insufficiency. The images were taken 
following removal of the renal capsule (left hand 
side) and its cut surface visible (right hand side) F: 
central mixoid area of the characteristically 




In the same year, papillary tumours became a separate entity on the basis of their 
avascular angiographic appearance, and their histological identification was also refined 
[63]. Nine years later Thoenes et al. described chromophobe renal cell carcinoma, a 
cancer with clear cell features, closely resembling renal tumours experimentally induced 
in rats [64] (Figure 5) . 
  
 
Somewhat later, collecting duct carcinoma with granular cell features was also 
recognised [65]. Significant overlaps, the clear and granular features and the marked 
clinical, pathological and phenotypic differences made the formulation of a new 
classification system necessary.  The new system that became known as the Mainz 
Classification was proposed by Thoenes et al., and it has been widely adopted. Renal 
carcinoma of tubular epithelial origin was classified on the basis of traditional histological 
criteria, and the entities described earlier were all included [66] (Table 7). 
Tumour types 
Clear cell  
Chromophil (eosinophil, basophil) 
Chromophobe (typical, eosinophil) 
Collecting Duct Carcinoma 
Oncocytoma 
Table 7. The Mainz Classification of renal tumours 
 
The Heidelberg/Rochester classification (1997) 
Concerns tumours are diseases of genetic origin. Because of this, it appears 
sensible that their classification should be based on the genetic deviations responsible for 
their emergence and progression. Loss of the short arm of chromosome 3 was identified 
as the characteristic feature of clear cell renal carcinoma [67], and the entities of the 
Mainz Classification have also been successfully paired with differential genetic 
characteristics [68]. These data were systematised by the Heidelberg/Rochester 
Figure 5. Chromophobe carcinoma. Its macroscopic appearance 
closely resembles that of oncocytoma 
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Classification [69, 70], the main aim of which was classification according to the 
histomorphological patterns characteristic of the entities separated on the basis of genetic 
differences. In other words, it can be applied in the course of routine histological 
examination, without a genetic test. The Heidelberg Classification (HC) has not been 
widely used [71]; however, it was adopted by the Rochester Classification as reflecting 
the consensus of the International Society of Urological Pathology (ISUP), except for 
differences in nomenclature and with supplementation of phenotypic descriptions (Table 
8). 
Benign parenchymal neoplasms  
Metanephric adenoma  
 
The characteristic genetic alteration is not yet known. 
Papillary renal cell adenoma Trisomy of chromosomes 7 and 17 and loss of the Y 
Chromosome. 
 
Renal oncocytoma Del 1p, 14q and loss of the Y chromosome or 
translocation between chromosome arm 11q13 and other 
chromosomes in a subset of tumours7,8. Many 
oncocytomas have an apparently normal karyotype. 
 
Malignant parenchymal neoplasms 
Common or conventional 
renal cell carcinoma 
Del 3p, (VHL mutation), Duplication of chromosome 
band 5q22, deletion of chromosome arms 6q, 8p, 9p, 
and 14q.  
Papillary renal cell carcinoma Trisomy of chromosomes 3q, 7, 8, 12, 16, 17, and 
20 and loss of the Y chromosome 
Chromophobe renal cell 
carcinoma 
LOH at chromosomes 1, 2, 6, 10, 13, 17, and 21 
and hypodiploid DNA content. 
Collecting duct carcinoma The characteristic genetic alteration is not yet known. 
Table 8. The Heidelberg/Rochester Classification 
 WHO classification, 1998: Histological Typing of Kidney Tumours 
It was mentioned in the Introduction that classification gave reflections of the 
actual status of our knowledge, and should be modified in parallel with the accumulation 
of experience. The classification continued to be based on histological criteria, i.e. on 
morphologically identifiable cell types and histological patterns. Attention was called to 
the importance of the degree of tumour differentiation, which was ranked by a three-grade 
scale. It was pointed out that vascular spread and tumour extension also have to be taken 
into account. Three benign entities were discerned, namely papillary/tubulopapillary, 
oncocytic and metanephric adenomas. Clear cell appearance of every possible size was 
invariably treated as malignant. Also, the granular cell type as well as spindle cell cancer 
constituted separate categories. Additional separate entities were papillary, chromophobe 
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and collecting duct cancers. This classification was, to a large extent, built upon the 
Mainz Classification and the chromophil type was discontinued. 
WHO classification, 2004: Pathology and Genetics. Tumours of the Urinary 
System and Male Genital Organs 
The clear cell type appearance was retained as a characteristic of malignancy. The 
separate category of granular cell type tumours, however, was abolished, because it was 
apparent that these do not differ from other entities either genetically or clinically, since 
clear cell type, papillary and chromophobe cancers as well as oncocytomas can also have 
an acidophilic appearance with granular cytoplasm [72]. The sacromatous (spindle cell) 
type also ceased as a separate category because it was realised that it was a poorly 
differentiated version of several tumour types. Papillary tumours, however, were divided 
into two groups, namely Type 1 small-cell and Type 2 eosinophilic papillary tumours 
[73]. Besides these, new entities such as familial renal cancer, translocation carcinoma, 
neuroblastoma-associated renal cell carcinoma, multicystic renal cell carcinoma, tubular, 
mucinous and spindle-cell renal carcinoma and mixed epithelial and stromal tumour were 
created. Also, the potentially aggressive epitheloid angiomyolipoma was described. 
Categories with mixed epithelial-mesenchymal morphologies as well as types resembling 
the primal nephric blastema also appeared among the groups added in 2004. Among 
benign entities, the subcategorisation of metanephrogenic tumours was completed, partly 
based on their discernibility on a genetic basis [74] (Table 9). 
Malignant renal cell tumours 
Clear cell renal cell carcinoma 
Multilocular clear cell renal cell carcinoma 
Papillary renal cell carcinoma 
Chromophobe renal cell carcinoma 
Carcinoma of the collecting ducts of Bellini 
Renal medulary carcinoma 
Xp11 translocation carcinomas 
Carcinoma associated with neuroblastoma 
Mucinous tubular and spindle cell carcinoma 
Renal cell carcinoma unclassified 






Metanephric stromal tumours 
Table 9. The renal tumour classification system used today 
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The Vancouver Classification (2013) 
This recent renal tumour classification system was created on the basis of the 
ISUP consensus, achieved after a review of the available abundance of published data. It 
listed fifteen morphologically separate entities with individual genetic characteristics, 
exceeding the WHO classification of 2004 by five subtypes. In a novel approach, newly 
recognised (separated) entities expected to be included in the next classification were also 
listed.  
The Vancouver Classification applied several new approaches and made 
numerous proposals for changes to the WHO Classification of 2004. Multicystic renal 
cell carcinoma of the clear cell group was classified as a neoplasia with low malignant 
potential. The separation of the two types of papillary renal tumours was mentioned, but 
the oncocytic variant was not classed as a separate entity. Hybrid oncocytic chromophobe 
tumour, a disease of indolent course may occur in three different ways, namely in the 
Bird-Hogg-Dubé syndrome, in renal oncocytosis and in the form of sporadic neoplasia. 
At present it is identified as chromophobe renal cell cancer; however, it would be more 
correct to classify it as an oncocytic tumour of uncertain malignity [75]. 
WHO classification, 2016: Tumours of the Urinary System and Male Genital 
Organs 
The fourth edition of the WHO ‘‘blue book’ published in 2016, contains 
significant modifications regarding renal tumours. Besides the introduction of five new 
entities based on the above-mentioned Vancouver Classification, important changes 
occurred in the definition of papillary adenoma and the terminology of the multilocular 
cystic renal neoplasm. The diameter of the former dramatically increased from 0.5 cm to 
the 1.5 cm. The growing data revealed that this larger tumour has no capacity to 
metastasise. The latter is supplemented with the term “of low malignant potential” as 
several publications report no recurrence or metastasis in patients with multilocular cystic 
renal neoplasm. 
The papillary RCC has traditionally been subdivided into type 1 and type 2 
papillary RCC. It has been assumed that a subset of tumours have mixed histology. 
Recent molecular studies suggest that type 2 papillary RCCs may constitute not a single 




 The 2016 WHO classification refers to names of subtypes that have been assigned 
on the basis of predominant cytoplasmic features (e.g., clear cell and chromophobe renal 
cell carcinomas, architectural features, anatomic location of tumours, and correlation with 
a specific renal disease background as well as molecular alterations pathognomonic for 
RCC subtypes or familial predisposition syndromes. In contrast to the 2004 WHO 
classification, familial forms of RCC, which also occur in sporadic form (e.g., clear RCC 
in patients with von Hippel-Lindau syndrome) are now mentioned with the corresponding 
sporadic tumour types in joint chapters [76]. 
The histological classification of renal tumours has undergone significant change in the 
past thirty years. New morphological, immunohistochemical, cytogenetic and genetic 
knowledge has led to an expansion of the number of entities (Fig. 6). Tumours of the 
organs lying within the domain of urology should also be divided into benign and 
malignant groups. The border between these two groups, however, are not always distinct 
– a well-known example being the uncertainty surrounding the classification of papillary 
renal tumour, a relatively common cancer occurring as adenoma or carcinoma –, and 
histological diagnosis and determination of the histological subgroup is of decisive 
importance. Electron microscopic, immunohistochemical and molecular tests and 
examinations have circumscribed types with different responsiveness to therapy and 
diverse prognoses, and have gradually revealed the mechanisms of their emergence and 
development. The Heidelberg-Rochester consensus had a major influence on the last two 
WHO classifications.  
 
Figure 6.  Increase in the number of renal tumour entities in successive classifications (Y 




IV/2 The possibility for genetic classification in the case of renal tumours   
The Heidelberg classification is essentially a histological classification, allowing 
the differentiation of various renal tumour types based on their microscopic phenotypes 
[69]. Genetic tests are required in the case of overlapping histological patterns. We sought 
to test the applicability of these genetic tests in three differential diagnostic problems 
occurring in the case of papillary renal tumours, using FISH (fluorescent in situ 
hybridisation): 
 a. Diagnostics of a rare composite tumour: papillary renal cell carcinoma 
embedded in an oncocytoma 
 b. Studies on genetic disorders considered characteristic of papillary cell 
carcinoma 
 c. Studies on the clonality of multiplex papillary kidney tumours. 
The Heidelberg classification uses chromosomal deviations to characterise the individual 
types and it can therefore be conveniently tested by centromer- and locus-specific FISH 
probes. 
A rare composite tumour: papillary renal cell carcinoma embedded in an oncocytoma  
A 68-year-old male patient with a long history of hypertension was hospitalised 
with upper right abdominal pain. Abdominal ultrasonography and CT revealed a 
thickened gallbladder, cholelithiasis of the common bile duct, and a tumour with a 
diameter of 4 cm in the upper pole of the right kidney. After treatment of the biliary 
problem, right-side nephrectomy was carried out. A histological examination confirmed a 
papillary type 2 carcinoma embedded in an oncocytoma. No recurrence or metastasis 
formation was observed during the 8-month follow-up period. 
Studies on genetic disorders considered characteristic of papillary cell carcinoma 
Tumours originally interpreted as papillary based on their phenotypic appearance 
were randomly chosen from the renal cancer material of the Institute of Pathology, 
Medical University of Pécs, reclassified according to the Heidelberg criteria. 
12155/92 L.J., female patient (68 yrs.): A tumour with a diameter of 5 cm located 
on the upper pole was removed by radical nephrectomy. No capsule involvement, pyelon 
or vein invasion or metastases were observed. 11644/96 N.D., female patient (70 yrs): No 
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tumour metastasis was identifiable. A tan-coloured, necrotic, haemorrhagic tumour 
measuring 8x7 cm, infiltrating the renal capsule was removed. 2384/97 E. J., male patient 
(54 yrs.): His multiple left-side renal tumours were incidentally recognised by 
ultrasonography. A histological examination revealed two greyish-white tumours 
measuring 6 and 2.5 cm in diameter, respectively. An extensive vein invasion was 
observed in the larger tumour (Figure 7). 7723/98 R. I., female patient (45 yrs.): Her 
right-sided renal tumour was incidentally recognised by ultrasonography. During surgery, 
a right-side adrenal metastasis was observed and radical nephrectomy was performed. 
    
3138/98 M.A., female patient (42 yrs. A tumour with a diameter of 17 mm was removed 
in the course of partial resection. 8439/98 A. I., male patient (60 yrs.): His large left-side 
renal tumour was recognised when examined for haematuria. Lung metastases were 
confirmed. A neoplasm with a diameter of 11 cm, intruding into the pyelon and the blood 
vessels was removed. 
Examination of the clonality of multiple papillary kidney tumours 
HA 473/99 Post-mortem description of the case of a male patient: He suffered 
from a chronic myeloproliferative disorder and died as a consequence of extensive 
thrombotic sequelae. An autopsy revealed two relatively large structures measuring 1.5 
and 2.5 cm in the left kidney, and small, well-defined, yellowish-white, pinhead- and 
pepper-sized ones on both sides. The diagnosis was “Adenoma papillare multiplex 
renum” (multiply papillary adenoma of the kidneys). 
FISH and IHC examinations 
Frozen sections were made from native tissues and placed on sylanised slides. 
After drying at 56 °C overnight, the sections were stained with DAPI, followed by 
Figure 7.  Double papillary renal tumour No. 2384/97 
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digestion by pepsin (Sigma Aldrich) for 18 min and optimisation of the digestion. For the 
isolation of nuclei, a frozen block of tissue with a diameter of 5 mm was subjected to 
mechanical separation, pre-digestion and cytocentrifugation. Hybridisation using alpha 
satellite probes specific for chromosomes 7, 17, Y and 8, 12, 16, 20 (Vysis Downers 
Grove, IL, USA and Cytocell Ltd., Cambridge, UK) and post-hybridisation washing were 
performed in accordance the manufacturer’s recommendations. In addition to the Y 
chromosome, a probe specific for chromosome 7 or 17 was used as a positive internal 
control. The evaluation was carried out in a Zeiss Axioscope fluorescent microscope. A 
sample containing at least one hundred nuclei was examined and the percentage 
distribution was calculated. Values larger than 2.8 signals/nucleus were treated as trisomy 
and those larger than 3.8 as tetrasomy. The most common signal/nucleus ratio is given in 
percentages. Here, deviated cell numbers larger than 15% are treated as a significant 
deviation. In Table 12, the chromosome numbers are colour-coded. 
IHC tests were performed on formalin-fixed, paraffin-embedded samples, making 
use of standard histopathological laboratory techniques. The antibodies applied, their 
manufacturers, clones and dilutions are shown in a publication [77]. 
The results of a FISH test on a frozen section are shown in Figure 8. On the left 
hand side, the nuclei of tubular epithelial cells show up in the cross-section of a normal 
renal tubule. In nuclei with normal karyotype, one green (Y chromosome) signal and two 
red (chromosome 7) signals can be seen. On the right hand side, a normal tubule is 
visible. On the other side the borderline between the tumour and the healthy tissue can be 
seen, where the normal tissue serves as an internal control. The green signal loss is visible 




Figure 8. The red signal marking chromosome 7 can be seen both in the renal 
parenchyma (a) and in the normal cells present in the papillary axes (b). The 
green signal marking the Y chromosome is present in tubular epithelial cells (a 
and b left side), but is absent in papillary tumour cells (b right side). Owing to the 




A rare composite tumour: papillary renal tumour embedded in an oncocytoma 
In all but one of the histological slides of a rare composite tumour, a papillary 
renal tumour embedded in an oncocytoma, polygonal cells with ample eosinophilic, 
granular cytoplasm and uniform, round nuclei were observed forming nests and tubules. 
Along whit an oncocytoma, a papillary lesion measuring 1 cm in diameter, with papillary 
and tubulopapillary structure was microscopically identified in one section. This area was 
characterised by less voluminous eosinophilic, granular cytoplasm and focal nuclear 
pseudostratification. Moreover, lighter cytoplasm was focally present. Macrophages with 
foamy cytoplasm and a small number of psammoma bodies occurred in the papillary 
axes. The nuclei were generally of low grade, but areas with increased nucleus/cytoplasm 
ratios and visible nucleoli were also present, resulting in Fhurman grade 2. The 
oncocytoma was diffusely E-cadherin positive and weakly CD 117-positive, but negative 
for vimentin and alpha-methylacyl-CoA racemase (AMACR). The papillary areas were 
CK7, AMACR and vimentin positive and E-cadherin and CD 117 negative. Also, there 
was no deviation in the numbers of chromosomes 7, 17,  
Studies on genetic abnormalities considered characteristic of papillary carcinoma 
The FISH results of randomly selected tumours reclassified according to the 
Heidelberg Classification (HC) and assessed as papillary on the basis of their phenotypic 
appearance, along with their key pathological characteristics are listed in Table 10. In five 
out of eight cases, at least one of the deviations in chromosome numbers was observed. 
Only in two cases (8439/98 and 6138/99) do pathological characteristics correspond to 
genetic criteria, confirming malignancy. In one case (12155/92), tetrasomy of only one 
chromosome occurring in adenoma was confirmed. In the case of a clearly malignant 
tumour (2384/97), only the deviation characteristic of adenoma could be observed. 
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Table 10.  FISH results of tumours classified as papillary based on their phenotypic 
appearances. The colour coding is the following: grey, loss of the Y chromosome; blue, 
monosomy; green, disomy; red: trisomy; brown, tetrasomy. (ND: no data). 
Examination of the clonality of multiple papillary kidney tumours 
Six of the multiple papillary tumours incidentally found in both kidneys in the 
course of an autopsy were examined for chromosome number deviations characteristic of 
papillary tumours. The data values were also contrasted with tumour sizes (Table 11). No 
Y chromosome loss was found in the tumours originating from male kidneys; however, at 
least one deviation in chromosome number, consistent with papillary tumours according 
to HC was confirmed in each of these tumours. The most coherent deviation was the loss 
of chromosome 20, exhibited by a high number of cells in all tumours. The number of 
chromosomal deviations was proportional to the tumour size. Four chromosomes were 






Table 11.  Results of FISH tests on multiple papillary renal tumours of a simple patient. 
According to HC, deviations in the numbers of chromosomes Y, 7 and 17 are indicative of 
papillary adenoma, and additional changes in those of chromosomes 12, 16 and 20 are suggestive 
of papillary carcinoma. The colour coding is the following: grey, precence of the Y chromosome; 
blue, monosomy; green, disomy; red: trisomy; brown, tetrasomy. (ND: no data). 
Case Diameter Pathological characteristics Percentage of cells 
  (mm)  Y 7 17 12 16 20 
 3138/98 17 Prognosis depends of behaviour - 81.2 75.4 39.9 ND ND 
 8439/98 110 Pyelon and vessel invasion 95.8 47.8 63.5 55.0 44.7 44.5 
12155/92 50 
Parenchyma or capsule 
invasion 
- 46.4 89.5 ND ND ND 
11644/96 80 Necrosis, capsule invasion - 90.8 ND 70.15 88.3 ND 
2932/97 40 Vessel invasion, tumour emboli  ND 87.5 90.9 87.8 ND ND 
7723/98 20 Invasion, adrenal metastasis - 81.2 75.4 ND 86.5 ND 
2384/97 60 Vessel invasion 95 50.6 59.3 92.5 ND ND 
6138/99 30 Renal cell cancer   95.1 55.8 54.2 65.1 50.2 ND 
 Diameter Percentage of cells 
 (mm) Y 7 17 12 16 20 
1. 5 95.3 48.4 69.1 91.7 97.5 83.3 
2. 15 93.7 84.0 88.6 39.6 93.4 89.9 
3. 5 98.1 47,2 63.9 75.0 85.4 88.3 
4. 15 93.2 49.3 55.8 77.0 94.1 73.1 
5. 4 96.4 50.6 63.5 90.6 96.8 75.4 
6. 25 ND 46.4 47.3 36.5 52.1 79.5 
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Today, carcinomas are regarded as genetic diseases. Hence, it seems sensible that 
their classification be based on the genetic deviations responsible for their formation and 
development. Efforts in this direction have been made for nearly all tumour types. In the 
case of renal tumours, this approach was realised in HC [69]. Based on the chromosomal 
deviations considered characteristic of the individual renal tumour types used as marker 
deviations, three benign and five malignant entities were differentiated (Table 8). The 
papillary growth pattern may be present not only in papillary, but also other types of 
kidney carcinoma. In these cases of overlapping phenotypical picture the genetic tests 
could help differentiate among them.  
 Based on post mortem data, the most common renal tumours are papillary tumour 
[78]. In the absence of obvious signs of malignanacy such as invasiveness and metastasis 
formation, the differentiation of benign papillary adenomas and carcinomas is based on 
their size. Clinicopathological and genetic data, however, reveal that biological behaviour 
is determined by genetic deviations rather than size [79]. Factors considered characteristic 
of papillary adenoma are the multiplication of chromosomes 7 and 17 and loss of the Y 
chromosome. Papillary carcinoma is characterised by numerical deviations of additional 
chromosomal regions and the duplication of the 1q region is a sign of fatal progression 
[80].  
 In situ hybridisation and its non-radioactive variants, namely the sensitive FISH 
and the chromogenic in situ hybridisation (CIS) that can be detected by traditional 
microscopy may be applied to test papillary renal tumours even in fine-needle biopsies 
[81, 82]. The first FISH test on a renal tumour in Hungary was carried out by the Author; 
using frozen sections of a papillary renal adenoma from an autopsy (see Figure 5). In 
addition to demonstrating the wider applicability of this technique, the objective of the 
test was to confirm the loss of the Y chromosome, viewed as a characteristic feature of 
papillary renal tumour. The results were first reported at the Conference of Pathology in 
Gyula, Hungary in 1998 [83]. It was later described by László Pajor, Professor of 
Pathology, who introduced the pathological application of in situ hybridisation in 
Hungary [84].  
We tested the diagnostic applicability of the genetic characteristics of papillary renal 




In the diagnostics of a rare composite tumour: papillary renal tumour embedded 
in an oncocytoma 
A tumour with a diameter of 4 cm was incidentally observed on the upper pole of 
the right kidney of a 68-year-old male patient. A histological examination after 
nephrectomy revealed a papillary type 2 carcinoma embedded in an oncocytoma. 
Although an oncocytoma and a renal cell carcinoma are separate entities, they may occur 
simultaneously in the same or in the contralateral kidney. Chromophobe renal tumours 
and oncocytomas can be closely related and they exhibit similar phenotypes of distal 
tubular origin, hence their joint occurrence is not surprising. Oncocytomas and papillary 
renal cell carcinomas, however, originate from different cell types. The occurrence of 
papillary renal cell cancer in an oncocytoma is extremely rare. Their joint occurrence has 
been reported by only two publications. The first of these was a 7-mm type 1 papillary 
carcinoma of a 75-year-old male patient embedded in an oncocytoma with a diameter of 
15 mm. The papillary tumour was readily identifiable in haematoxylin-eosin stained 
sections, based on its appearance clearly separated and differing from the surrounding 
oncocytoma. In contrast to the case studied in our laboratory, the papillary tumour cells 
showed trisomy of chromosome 7. The second case was that of a 73-year-old female 
patient, who had a 1.5-mm papillary tumour within an oncocytoma with a diameter of 36 
mm. Although no chromosome examination was performed, the typical morphology and 
the immunohistochemical results confirmed the diagnosis. 
In our case the diagnosis of a combined tumour, a papillary renal tumour 
embedded in an oncocytoma was based on microscopic morphology and 
immunohistochemistry [77]. In certain regions the two tumour types were sharply 
divergent; in other foci they exhibited morphologies that were difficult to differentiate. To 
proceed further, we decided to apply immunohistochemical techniques. In view of the 
size and the structure of the lesion and the immunohistochemical pattern, the diagnosis 
was type 2 papillary carcinoma within the oncocytoma. No deviations were observed in 
FISH tests using centromer-specific probes for chromosomes 7, 17 and Y. 
 Testing for genetic deviations considered characteristic of papillary carcinoma 
Reclassification, by using microscopy, of the renal tumour material of the Institute 
of Pathology, Medical University of Pécs according to HC was completed earlier [85]. 
According to HC, tumours judged papillary based on their phenotypic appearance can 
only be further classified as “adenoma” or “carcinoma” by genetic tests. Deviations in the 
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number of chromosomes Y, 7 and 17 are indicative of papillary adenoma, whereas 
additional numerical deviations of chromosomes 12, 16 and 20, are indicative of papillary 
carcinoma (Table 8). FISH tests on eight tumours diagnosed as malign on the basis of 
clinicopathological evidence produced mixed results (Table 11). Only in two of the eight 
cases were the HC criteria met, i.e. deviations supporting malignancy observed. In one 
case the genetic test only confirmed adenoma, even though malignancy was corroborated 
not only by the size but also by vessel invasion. In each of two other cases, only one 
chromosome was affected, which is insufficient for classification. In three cases, no 
deviations were detected. Our results are in good accordance with the data published by 
Klatte et.al. from UCLA in California [86]. According to the University of California at 
Los Angeles Kidney Cancer Program Database, 1825 patients were treated with renal 
cancer between 1985 and 2007; 158 papillary renal carcinomas were identified according 
to the histological criteria of papillary tumours [87]. In 65 consecutive cases cytogenetic 
tests were performed. Deviations were found in 57 cases (88%).  Trisomy of chromosome 
7 was observed in 35 cases (54%), that of chromosome 17 in 31 cases (48%), that of 
chromosome 12 in 28 cases (43%) and that of chromosome 16 in 22 cases (34%). These 
results are quite similar to those obtained on our non-representative material. We found 
deviations in the number of the relevant chromosomes in 6 out of 8 cases (6/8, 75%): 
chromosome 7, 5/9 (62%); chromosome 17, 3/8 (38%); chromosome 12, 3/8 (38%); 
chromosome 16, 1/8 (13%). Brunelli et al. examined 10 adenomas and the same number 
of carcinomas using the FISH technique, but defined no threshold value; however, when 
they found trisomy in one cell, they considered the tumour was involved. They examined 
the normal parenchyma surrounding the tumour using the same methods. In all 20 cases 
(10 adenomas and 10 carcinomas), they tested the six relevant chromosomes (7, 12, 16, 
17, 20 and Y). They did not find a case without at least one cell exhibiting a deviation of 
at least one chromosome! However, they did not find any deviation more frequent than 
12%. Using these criteria and with the given test sensitivity, the frequency of tri- or 
tetrasomy in the adenomas was 90% for chromosome 7, 70% for chromosome 17, 40% 
for chromosome 12, 50% for chromosome 16 and 50% for chromosome 20. Nearly the 
same distribution of deviations was found in the carcinomas: the frequency of numeric 
anomalies was 100% for chromosome 7, 70% for chromosome 17, 50% for chromosome 
12, 60% for chromosome 16 and 40% for chromosome 20 [88]. If the frequency of 
deviations observed in normal renal tissue (i.e. 12%) is chosen as the threshold value, the 
Californian and Hungarian data are quite similar. However, it is also evident from the 
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work of Brunelli et al. as well as from our own findings that adenoma and carcinoma 
cannot be classified only on the basis of the genetic characteristics defined in the HC [88]. 
Studies on the clonality of multiplex papillary kidney tumours 
Partial nephrectomy, a technique applied with increasing frequency entails the risk 
of recurrence due to the presence of residual tumour cells. 7–25% of renal cancers are 
multifocal, which is a consequence of either tumour seeding within the organ or the initial 
multifocal character of the tumour [89]. In the case of multifocal clear-cell renal cancers, 
monoclonality (i.e. tumour seeding within the organ) has been confirmed [90]. However, 
papillary renal cell cancer is the most common renal cell tumour. In the course of 14,763 
post mortem examinations, Wunderlich et al. found 260 renal tumours, 36 of which 
(18.95%) were multifocal [91]. Applying the findings of molecular genetic tests, papillary 
tumours are polyclonal, i.e. they emerge independently [90]. Our studies yielded the same 
result. Although the frequency of chromosomal deviations considered specific by the HC 
increased in proportion to tumour size, this was not coherent; polyclonality, however, was 
apparent. 
IV/3  Bladder tumours 
The international reference centre responsible for the histological classification of 
the tumours of the male urogenital tract was initiated by the WHO in 1965. Five hundred 
histological sections and the associated clinical data were sent to the collaborating 
institutions for preliminary classification. The results were then summarised by eight 
pathologists in 1968. Each entity was supplemented with a description and 
photomicrographs. Needless to say, attention was called to the fact that the classification 
reflected contemporary knowledge. As a result, the nomenclature became more uniform. 
At that time, the designation “transitional cell” rather than “urothelial” was used; 
however, terms such as “epithelioma” were successfully eliminated. At that time the clear 
separation between benign and malignant tumours had not yet been achieved. 
In the second edition, attention was called to the fact that, even though the 
designation “transitional cell” was widely used, the urothelium is an independent 
epithelium type, and it is more practica to designate its tumours as “urothelial”. Owing to 
the wide contemporary use of the former, the two designations were treated as equivalent. 
Papillary neoplasia of low malignant potential was introduced, for tumours which had 
previously been classified as a highly differentiated carcinoma. It was not coherent to 
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include atypia/dysplasia in in situ urothelial cancer and classify its variants as a malign 
subgroup, since the former is ambiguously non-malignant, the latter is only a 
premalignant state. However, the designation of transitional cell cancers as squamous or 
glandular “metaplasia” was eliminated, in accordance with the present-day terminology, 
according to which metaplasia means the transformation of one differentiated tissue free 
of malignancy into another one. Also new entities were created, namely adenocarcinoma, 
urachal, clear cell carcinoma and small cell carcinoma. A new epithelial abnormality was 
hyperplasia, which may be either flat or papillary in appearance. Besides this, new 
tumour-like lesions were labelled myofibroblastous tumour and postoperative spindle-cell 
nodule. 
The third classification applied the designation “urothelial” exclusively and the 
notion of transitional epithelium was rejected. Several new subtypes were described. 
These were de novo squamous cell and glandular carcinomas, now constituting a separate 
group with several additional members like nested, microcystic, micropapillary, 
lymphoepithelioma-like, plasmocytoid, sacromatous and giant cell carcinomas. Small cell 
tumours were moved to the novel group of neuroendocrine carcinomas. 
The fourth edition of WHO classification brought few changes. The urothelial 
proliferation of uncertain malignant potential was introduced among the noninvasive 
urothelial lesions. Urothelial carcinoma has long been known to have a remarkable 
propensity towards divergent differentiation, which is observed most commonly in 
association with high grade and locally advanced carcinomas. The incidence in 
cystectomy specimens can reach 33% and this is generally associated with aggressive 
behaviour.  Therefore the previously used term “infiltrating urothelial carcinoma“ is 
supplemented with the definition “divergent differentiation” and it is recommended that 
pathologists report the percentage of divergent histologies. The new entity represents the 
tumours that arise from a bladder diverticulum.  
IV/4 Prostate tumours 
In the first classification of the prostate tumours, published in 1981 it was not 
known whether a real benign epithelial tumour (adenoma) or stromal tumour (leimyoma 
or fibroma) actually exist or these circumscribed tissue excesses are rather simply 
hyperplasias. Thus only a single benign lesion, namely papillary adenoma was included, 
which was retained unaltered in the second edition, but was absent from the third one. At 
that time the various forms of adenocarcinoma, such as small and large acinar, cribriform 
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and solid, were still used as designations of histological subtypes; however, they are 
completely absent in the next classification because they were incorporated into the 
Gleason grade system. The categorisation of prostate cancer in the first two classifications 
as clinical, occult, incidental and latent carcinoma is quite interesting. The latter meant 
tumours detected in the course of an autopsy and, similar to the other categories, 
represented tradition rather than individual histological entities. It is due to this 
shortcoming, among others, that “Histological Typing of Prostate Tumours” was viewed 
as the least valuable volume of the WHO series by the recension of the Journal of Clinical 
Pathology [92]. Nevertheless, these categories were retained in the second edition. 
Significant advances in the latter were the appearance of preinvasive prostate 
intraepithelial (PIN) carcinoma and the recognition of the neuroendocrine type. 
In the third edition, the three-grade classification of PIN, applied from the 
beginning, was simplified to a more reproducible two-grade system, but it emphasised the 
difficulty of making a reliable distinction between low grade PIN and normal and 
hyperplastic epithelium. A single benign epithelial tumour called basal cell adenoma was 
retained. Moreover, the morphologies of the various Gleason grades were elaborated 
upon. In 2005, a shift took place, making Gleason 6 rather than Gleason 7 the most 
frequent pattern. At the same time, this also led to an embedding of the Gleason 
classification [93].   
The fourth edition of the WHO classification appeared in the 2016, which 
contained two important changes, along with the description of the latest results of 
prostate cancer genetics and its immunophenotype. One of them is a new modified 
Gleason grading diagram where every form of cribriform and poorly formed tumour 
glands are included as a Gleason pattern 4. It is recommended that pattern 4 percentages 
be reported if it is the highest grade within the Gleason score 7, because a low percentage 
of pattern 4 may be treated with active surveillance. The other is the introduction of the 
recently developed grade groups system called the ISUP grade, which more accurately 
reflects the prognosis and is better suited than the Gleason score in a clinical context.    
IV/5 Testicular tumours 
In order to achieve a uniform histological classification of testicular tumours, a 
classification by experimentalists was compiled in 1971, which was applied to 250 cases 
in 12 centres. The finalised system was published later in 1973. The notable similarities 
between testicular tumours and ovarian tumours were also taken into account. The 
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significant differences in occurrence, age distribution and clinical behaviour, however, 
ruled out the possibility of applying an identical classification for both groups. Here, 60% 
of testicular tumours display a mixed histological character. In spite of this fact, even the 
first classification may be considered successful, as it has been subjected to relatively few 
substantial modifications. In the second edition, just like that for prostate tumours, the in 
situ stage of germ cell tumours is included as well. It is supplemented by some smaller 
entities and some, such as dermoid cysts, are treated as distinct. One of the most 
significant changes of the third edition was the inclusion of the malignant group for both 
the Leydig and Sertoli cell tumours.  
The biggest differences between the 2016 WHO classification and the previous 
version concern the germ cell tumours. These tumours arise from the progression of 
intratubular malignant germ cells. Such cells were usually designated as either carcinoma 
in situ or intratubular germ cell neoplasia. The use of different terms for the identical 
lesion had been a source of some confusion, so germ cell neoplasia in situ (GCNIS) was 
proposed. The germ cell tumours are now broadly separated into two quite different 
groups, namely those derived from GCNIS and those unrelated to GCNIS based on 
genetic, prognostic and clinical differences [76]. 
IV/6 Penile tumours 
The vast majority of malignant tumours of the penis are squamous cell 
carcinomas. Most previous classification schemes were exclusively morphology based. 
The 2016 WHO classification presents a new classification based on clinicopathologic 
uniqueness and its connection with human papillomavirus (HPV) infections [76]. 
V. Results 
 Besides the histologic type, the most important of a malignant tumour is the 
stage, since this is what will determine the post-operative treatment as well as prognosis. 
TNM-based staging will have been used for half a century and it has become widely 
accepted. One reason for its success is that it is easy to use and can be applied to all the 
different organs. Its general acceptance due to a broad-based consensus made possible the 
performance of clinical studies with increasing case numbers and a comparison of 
different treatment procedures. However, it has to be applied with circumspection, 
because the TNM system is under continuous change, not only when new editions appear 
about every five years, but also due to the in-between revisions. (There have been three of 
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these, namely in 1973, 1982 and 1992). During the comparison of consecutive issues, 
special attention should be paid to the fact that although the notation system of pTNM, 
i.e. pT, pN, pM and their subcategory labels do not change (with a few exceptions, such 
as the appearance of the V and S categories), the underlying content does. In other words, 
if earlier categories need be translated to the updated nomenclature, it may be impossible 
to do so. For example, a pN classification based on size cannot be compared to another 
based on the number of lymph nodes or their localisation. 
VI/1 The directions of evolution of the stage classification 
When changes in the pTNM system of urological tumours are depicted in graphical 
form, it is apparent that the degree of changes is constant and continuous (Fig. 9).  
 
Figure 9. The pTNM system of urological tumours is continuously changing. (Y axis: 
number of changes, X axis: year of editions.) 
This is not reassuring, because a trend in development is not visible here. Ideally, one 
would like the number of necessary modifications to decrease over time and the 
codification system to stabilise. 
When, however, pT and pN components are analysed separately (pM was practically 




Figure 10. Changes in pT categories pointing towards stability. The exceptions are the 
kidney and the penis. (Y axis: number of changes, X axis: year of editions.) 
Changes in the classifications of testicular and bladder tumours have already shown a 
decreasing tendency in earlier editions, and the same can be observed for prostate 
tumours in the last edition. In contrast, the number of modifications in the classification 
of kidney tumours has increased in the last three editions and that of penile tumours in the 
last two editions. The stage classification of lymph nodes has displayed significant 
variations from the beginning, without any sign of stability, if we ignore the lymph node 
categories of testicular cancer in the last edition (Fig. 11).  
 
 Figure 11. The stage classification of lymph nodes has had significant variations, without 
any indication of stability, if we disregard the lymph node categories of testicular cancer 
in the last edition. The prostate curve totally and the urinary bladder curve partially 
covered by other organs.)  (Y axis: number of changes, X axis: year of editions.) 
The TNM system essentially describes the involvement of anatomical structures, 
or defines categories based on tumour size. Over the years, attempts have been made to 
incorporate as many prognostic factors as possible. This, however, endangers its ease of 
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use and its ease of comparability over different organs, which helps explain the efforts 
made by some to preserve the TNM as a purely anatomical system. The most important 
engines of the development of it were: studies which presented growing numbers of cases 
with their prognostic data on one hand and the increasingly precise systematisation of 
knowledge with more accurate definitions, the wide dissemination of concepts and the 
incorporation of other systems on the other. However, among these factors there are no 
new clear methodologies and cut-up standards. It may not be an exaggeration to say that, 
had he been given the seventh TNM Classification Atlas, a pathologist active at the 
beginning of the last century, using the techniques available at that time, could have 
provided a stage classification that might be valid even today. 
 Our study has revealed that the successive TNM classifications might be regarded 
as stations of a slow process of development. This is corroborated by the decreasing 
number of modifications in the description of primary tumours. Up until now, an 
increasing number of stages have retained their meaning over more and more editions. It 
is also of interest to look at the organs and stages that still display a considerable 
variation. This knowledge is useful not only for the researcher, but also for the practising 
physician, because it is not sufficient to know the rules – their meaning and limits also 
need to be clearly recognised. However, studies based on increasing numbers of cases 
provide little assistance in promoting development and resolving the uncertainties of 
stage classification; and small statistical shifts themselves should not be considered 
conclusive. 
In our opinion, up to now the examination methods and their standardisation have 
received insufficient attention. The pathological stage is mostly determined by 
microscopy. The areas to be examined have to be selected, but this is done visually, 
retaining a significant subjective component in the examination method. One way to 
reduce this subjective factor may be to embed the entire organ and apply a suitable, 
accurate procedure along geometrical lines. Urology is fortunate in this aspect, because 
all the organs treated readily lend themselves to this approach. The necessary procedure 
was implemented some time ago for the prostate. The anatomical structures of samples 
derived from the kidney, the testicle and the penis are somewhat more complicated than 
those of the prostate, but still do not attain the complexity of a cystoprostatectomy 
sample, representing seven organs (urethra, prostate, two seminal vesicles, bladder, and 
two ureters). We therefore applied a geometric approach to develop a cut-up protocol that 
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was easy to use in everyday practice for the stage classification of radial cystectomy 
samples [33]. 
V/2 The advantages of the GDPRC in radical cystectomies  
Radical cystectomy preparations can be complexes of seven organs in case of 
males. At present their involvement is still being examined in a non-standardised fashion, 
depending to a large extent on the subjective assessment of the pathologist performing the 
cut-up. We identified this circumstance as a fundamental cause of the scattering of 
published pathological stage frequencies. Taking into consideration the above statement 
of Donald G. Skinner, doyen of American urology, we devised a protocol that allows the 
embedding of the entire sample. Based on 138 cases, we found that the findings 
accurately reflected the statistical average of 15,586 cystectomies. The deviations were 
due to more detailed processing: the case numbers of the pTis-pT2 group turned out to be 
lower and those in the pT3-pT4 group to be higher. In the case of pT4, the difference was 
significant (11.36% vs. 16.6% p= 0.049) [33]. It was later found by a research group in 
Aachen that processing a whole organ is not necessary for a more accurate stage 
determination. They, however, used a self-created category, the so-called pTsum (= 
“sum” means the stage of cystectomy and the preceding TURB stage together) as a 
baseline, and did not perform an examination based on the canonical TNM system [94]. 
As is evident from our historical review of bladder tumour staging, the inclusion of the pT 
stage of preoperative TURB is by no means new. The Jewett-Strong-Marshall 
classification in 1952 took into account the TURB stadium obtained one month before 
cystectomy [6]. However, the fact that this has not been incorporated in the TNM system 
is quite apparent to us, as a cystectomy stage should demonstrate the situation in the 
respective sample. Nevertheless, we found that pTsum, to some extent, reflects the 
statistical data from a large number of cases, which are generated after embedding the 
entire sample [95]. Interestingly, Gaisa et al. asserted that the biological behaviour of the 
tumour is better reflected by pTsum than by the traditional pTNM system. Although they 
agreed with the greater accuracy of embedding the entire sample, they did not consider it 
more useful [96]. Even though the indication of pTsum appears worthy of consideration, 
its prognostic significance as one of the main objectives of the TNM system is basically 
called into question by the survival data reported by Gaisa et al.. Namely, after the first 
twenty months, a larger number of cases with pTsum category 1 died than cases with 
pTsum category 2 [97]. We think that the embedding of the entire sample is a progressive 
technique. Intravesically administered, molecular targeted anti-tumour therapies are 
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expected to become available soon, and other, more conservative treatments and screens 
may also become more efficient. Consequently, we will certainly have to examine an 
increasing number of small, partially regressing tumours and we won’t be able to rely 
solely on our human senses. 
V/3 Incorporation of new scientific results provides the basis for changes in 
histological classification 
The development of histological classification – unlike that of pathological staging – 
has been definitely driven by new methodologies. The initial light microscopic images 
have been supplemented by immunohistochemical data and, most recently, the 
discrimination of new entities has been made possible by genetic information, as for 
instance in the case of renal Xp11 translocation carcinoma. Since carcinomas are rooted 
in genetic disorders, it is sensible to classify them on the basis of genetic factors 
responsible for their development. Since these initial genetic factors cannot be corrected 
in the course of tumour evolution, they appear more coherent than images of the 
microscopic phenotype in the course of clonal propagation. Among urological tumours, a 
progressive, genetically based classification has so far been published for only one 
urological tumour type, namely renal tumours (Heidelberg/Rochester classification). Our 
review of the development of histological classifications, however, has revealed that 
although genetic information about kidney cancer has greatly increased, to date there is 
no widespread acceptance of a purely genetic classification system. 
V/4 Histological and genetic classification in the case of papillary renal tumours 
Our studies were carried out about five years before the publication of the 
comprehensive reviews cited before [86-91]. Our intention was to utilise the HC in 
diagnostic practice, on the basis of the chromosomal disorders described in the 
publications that laid its foundations, because the chromosomal deviations described by 
the HC appeared highly coherent and diagnostic [98, 99]. We reported our results at the 
Congress of the Hungarian Society of Pathologists, held in Gyula Hungary in 1998 [80]. 
Since our results did not fall into the accepted “mainstream”, we did not attempt to 
increase the case numbers or publish our results. The research team working in 
Heidelberg has since published data that conforms with the HC [80]. Nevertheless, 
neither the WHO classification immediately following the HC, nor the last Vancouver 
Classification has adopted the differentiation of renal tumours based only on genetic 
differences. Chromosomal deviations that may be linked to renal tumours are listed, 
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together with immunohistochemical data, as characteristics to support the microscopic 
image of the phenotype. Our own studies have also confirmed much the same thing. In 
the case of the papillary renal tumour embedded in an oncocytoma, its histological type 
was successfully verified in spite of the fact that it did not exhibit the chromosomal 
deviations that are characteristic of it. We were able to do this, because similar 
conclusions had been drawn in our earlier studies on papillary renal carcinoma and 
multiple papillary tumours. After realising that carcinomas are basically genetic diseases, 
great interest was focused on the genetic classification of renal tumours, embodied by the 
HC. Our findings are in general agreement with the data presented in the literature; 
however, as our genetic knowledge is at present still limited, more accurate genetic 
information regarding tumour evolution will have to be collected. 
VI Summary of the results 
Stage and histological type are key histopathological parameters, but the 
consecutive stage and histological classifications display significant differences. They 
vary and are unstable from a practical point of view. However, do the ever-newer 
classifications represent steps towards an evolution? Or are they merely a rearrangement 
of our knowledge supplemented by new, mostly statistical data as part of an endless 
process? To date, we have not found a study that investigated the development of the 
TNM system and the histological classification of urological tumours. Therefore we 
reviewed the successive editions of the WHO and UICC classifications. Our study has 
revealed that these might be regarded as stations of a slow process of evolution towards to 
the stabilisation. We though that improvement of methodology of staging and histology 
assessments, using a more precise procedures and modern examinations processes can 
accelerate this development.    
 This was why we introduced a new cut-up protocol of urinary bladder cancer to 
decrease pathologist subjectivity and we examined the applicability of genetic 
classification in the differential diagnostics of papillary kidney tumours. Nowadays both 
procedures are an integral part of our daily routine. Knowing their limitations, they prove 
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A radikális cystectomiás minta teljes 
szövettani feldolgozásának módszere és 
költségkihatása 
The methodology and the expenses of the macroblock evaluation of the cystectomy specimen 
Lapszám: Magyar Urológia | 2012 | 24. évfolyam 2. szám 
Összefoglalás: A szerzők 138 radikális cystectomiás preparátum teljes makroblokkos 
szövettani feldolgozását végezték el 2008 és 2012 között, természetesen a kivett 
regionális nyirokcsomókkal együtt. A közleményben a patológiai feldolgozás új 
módszerét ismertetik. Ez elméletileg kizárja, hogy szemben a korábbi célzott 
kimetszésekkel, bármilyen daganat, vagy daganatrész rejtve maradjon. A szerzők a 
módszer jelentőségét a pT0, illetve pT2B, és a pT3A stádiumok vizsgálatában, valamint a 
prosztatára terjedés esetében hangsúlyozzák. 
 
SUMMARY: The authors performed macroblock evaluation of 138 cystectomy specimen 
between 2008 and 2012, together with the regional lymph nodes. New concept was 
presented the total pathological working up even in male and in female bladder. On the 
contrary of the previously applied systemic sections, the total oriented elaboration 
excludes undiscovered tumors or tumor parts. The authors emphasized the importance of 
the method especially in pT0, pT2B, pT3A and pT4 cases if the tumor invades the 
prostate. 
  
A klinikai döntésekben – és a prognózis meghatározásában – legfontosabb adat a 
hólyagdaganat stádiuma. Sajnos ez még a korszerű képalkotó-vizsgálatokkal is csak igen 
nagy tévedéssel állapítható meg, így döntő a kórszövettani vizsgálat maradt (1). A TUR-
ból nyert szövettani preoperatív eredmény viszonylag még a legmegbízhatóbb, de a 
mintavétel hibájából adódóan ez is szignifikánsan eltér a cystectomiás preparátum 
stádiumától. Kérdés az, hogy az arany standardnak tekintett cystectomiás anyag 
patológiai feldolgozása vajon teljesen megbízható-e? Nem lehetséges-e, hogy a 
hólyagban lévő egyes daganat vagy daganatrészek nem kerülnek kimutatásra? A jelen 
nemzetközi és hazai gyakorlatban a hólyagból makroszkópos irányítással történnek a 
kimetszések, és csak ezek a részek kerülnek beágyazásra, illetve feldolgozásra. A 
kimetszésen kívüli területek rejtve maradnak, így a daganat kiterjedtségére vonatkozó 
adatok egy része elvész. Más szervek esetén is egyre gyakoribb a makroblokkos 
feldolgozás. Polgárjogot nyert már az emlődaganatok esetében, és mind kiterjedtebben 
alkalmazzák prosztatarák vonatkozásában is. A teljes feldolgozásnak a klinikai 
szempontokon túl tudományos értéke is van, ami által valóbb képet nyerhetünk a 
hólyagrák biológiai viselkedéséről. A teljes szövettani feldolgozás hazai elterjedését a 
szűk anyagi lehetőségek korlátozhatják. 
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 Anyag és módszer 
   
A Szegedi Tudományegyetem Urológiai Klinikáján 2008 és 2012 között operált 138 
radikális cystectomiás preparátum makroblokkos feldolgozása történt meg. A minták 99 
férfitől és 39 nőtől származtak. Az átlagéletkor 62,28 év volt. A férfiaké 64 év 
(legfiatalabb 41, legidősebb 76), míg a nőké 60,56 év (legfiatalabb 49, legidősebb 71). 
A mintákat 10%-os formalinban fixáltuk, minimum három napig. A metszési síkokat 
sematikusan az 1. ábrán szemléltetjük, és ezt orientált kivágási protokollnak neveztük el 
(OKP). A férfi és női hólyag feldolgozása természetesen jelentősen különbözik (1. ábra). 
1. ábra Javasolt kivágási protokoll sematikus ábrázolása, férfi (A) és női (B) 
cisztektómiákra. A melső falon vezetett orientációs bemetszést követően képzett metszési 
síkok: 1: urethra reszekciós vonal és apex, 2: prosztata hátrafelé szélesedő harántszeletek, 
3: hólyagbázis 12 sugárirányú kimetszése, 4: húgyhólyag haránt szeletek, 5: kupola 
szagittális metszetei. (A sorszámozás aluról fölfelé a feldolgozás sorendjében történt.) 
 
  
Férfihólyag esetén a kivágás lépései (1. A ábra) 
  
• Urethralis reszekciós vonal,  
• a prosztata ék alakú metszete,  
• a hólyagalap sugárirányú metszetei a prosztata kraniális széllel,  
• hólyagtest harántszeletek,  
• hólyagkupola,  





 Női hólyag esetén a kivágás lépései (1. B ábra) 
 • A méh és kétoldali függeléke, a mellső vaginafallal együtt el lett választva a hólyagtól 
és így feldolgozva,  
• a húgycső harántszeletekben,  
• a hólyagalap szintén haránt irányban,  
• a hólyagkupola a férfihólyag feldolgozással egyezően,  
• a nyirokcsomók egészben, nagyobbak félbevágva mindkét nemben (2. táblázat ). 
Ha a metszlapon fontosnak ítélt elváltozást találtunk, azt két szemközti metszési síkban is 
megjelenítettük. A szövettani leletezés a metszetek áttekintésének meghatározott 
sorrendjében történt, egy erre kidolgozott adatlap felhasználásával (2. ábra). A lelet 
szöveges formában összegezte a feldolgozó patológus véleményét (3. ábra). 
2. ábra A makrometszetek kiértékelését segítő adatlap. Bal oldalon a sematikus, jobb 
oldalon a számszerűsített értékek megadásának lehetőségével 
 








Az OKP-t a Szegedi Egyetem Pathologiai Intézetében 2008-tól napjainkig, minden 
radikális cystectomiás minta esetében, napi rutinfeldolgozásként alkalmazzuk. 2012 
márciusáig összesen 138 vizsgálat történt. A 124 preparátum mérete átlagosan: supero-
inferior: 101,6 mm (legkisebb 40 mm, legnagyobb 170 mm). Medio-laterális: 92,7 mm 
(legkisebb 40 mm, legnagyobb 140 mm). Antero-posterior: 75,7 mm volt (legkisebb 35 
mm, legnagyobb 130 mm). 119 eset átlagos tömege: 308 g (legkisebb 46 g, legnagyobb 
680 g). 
A makroblokk 7 mm vastag hólyagfali és 5 mm legnagyobb vastagságú prosztata-szelet 
készítését tette lehetővé. 
A hólyag, illetve a prosztata feldolgozásához átlagosan 9,2 db makroblokkot, valamint 14 
standard blokkot használtunk fel. A férfiak radikális cystectomiája esetében átlag 9,82 db 
makro, 16,3 db standard blokkot készíttettünk (4. ábra). A nők cystectomiája esetében 
8,76 db makro, 9,6 db standard blokkot használtunk fel (5. ábra).  
A stádiumot a 2002-ben átdolgozott AJCC/UICC TNM rendszert használva határoztuk 
meg (2). Az eredményeket a 1. táblázatban mutatjuk be. Obturátor nyirokcsomó 126 
esetben (91,3%) került eltávolításra. Az eltávolított nyirokcsomók stádiumonkénti 
megoszlását és az áttétes nyirokcsomók arányát a 2. táblázat mutatja. Két esetben a nem 
értéklehető nyirokcsomó konglomerátum nem került beszámításra (1. táblázat) (2. 
táblázat).   
Egy makrometszet előállításának fogyóeszköz költsége: 1,8 euró, míg egy standard 
szövettani metszeté 0,25 euró volt. A férfi radikális cystectomia OKP szerinti 
feldolgozásának fogyóeszköz és vegyszer költsége átlagosan 21,8 euró míg a női 
cystectomiáké 18,2 euró volt. Egyszer beszerzendő eszköz igénye a rotációs mikroszkóp 
makro fej 1200 euró. A kivágás fotódokumentáció készítésével kettő, a mikroszkópos 
vizsgálat, további két patológusi munkaórát vett igénybe. 









1. táblázat Az OKP szerint feldolgozott 138 radikális cystectomia stádium megoszlása 
 







A cystectomiás preparátum teljes feldolgozásának igénye a napi diagnosztika gyakorlata 
számára már több mint 10 éve felmerült. Hiszen könnyen belátható, hogy a makroszkópos 
kivágások között a daganat vagy daganatrész, esetleg daganat megelőző állapot rejtve 
maradhat. A húgyhólyagok egészben való feldolgozását először Soto és munkatársai 
végezték (3), összesen 45 esetben úgy, hogy a vizsgálat előtt a hólyagot celluloiddal 
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töltötték fel. A szerzők többsége „térképezési” eljárást alkalmazott, azaz a preparátumot a 
húgycső hosszanti tengelye mentén felhasították és horizontális szeletekben dolgozták fel. 
A gyakran igen nagyszámú metszet áttekintése nehézkessé válik. Továbbfejlesztett 
változatban a hólyagot négy qudránsra osztották, így jobban kiteríthetővé vált. Az 
esetenként így keletkezett 5-100 kimetszés összeillesztése a szövettani feldolgozás után 
bonyolult lehet, ezért a részeket különböző jelölésekkel látták el, és ezeket egybe 
illesztették (4). A középvonalban vezetett szagittális metszés utáni, két hólyagfél 
szövettani feldolgozása látványos és egy-egy közleményben, ilyen óriás blokkokról 
számolnak be (5). Nagyobb, a hólyag űrterébe bedomborodó daganatoknál ez a módszer 
technikailag szinte kivitelezhetetlen. 
A cystectomiás minták rutin patológiai feldolgozását jelenleg Rosai és Ackerman 
kézikönyv összegzi (3. ábra). Ezt alkalmazzák a legszélesebb körben, mert meghatározza 
a legfontosabb anatómiai helyeket, és előírja, hogy a férfi hólyagból legalább 25 
kimetszést kell végezni. Elgondolkoztató, hogy ebből csak három kimetszés reprezentálja 
magát a daganatot (13). 
A jelentős számú cystectomiás OKP feldolgozás anyagunkban kiküszöbölte a 
makroszkópia vezérelte kivágás tévedési lehetőségét és teljes képet adott az anyagról. 
Rutin alkalmazása az anyagi és munka ráfordítás növelésével bevezethetővé vált. 
Nyilvánvaló előnyei leginkább bizonyos kritikus stádiumokban jelentkeztek. 
Például egyértelművé teszi a pT0 stádium kórismézését, hiszen biztosan nem marad 
tumor a kimetszés közötti részeken. Pontosan meghatározhatóvá vált az elkülönítés a 
pT2A és pT2B között. A belső és külső izomréteg tumoros infiltrációjának klinikai 
jelentősége még nem egyértelmű, és ennek egyik magyarázata, hogy a patológiai 
feldolgozás csak makroblokkos formában képes a pontos elkülönítésre (6, 7, 8, 9). A 
pT3A stádium szabad szemmel nem látható, így szerencsétlen esetben nem kerül a 
megfelelő rész a kivágásba, pedig klinikai jelentősége adott (10, 11). Az OKP talán 
legfontosabb értéke, hogy egyértelműen meghatározhatóvá teszi a prosztata daganatos 
infiltrációját, a pT4A stádiumot, mert a két szomszédos szerv így egy szövettani 
metszetben vizsgálható (12). A stádiumtól függetlenül az OKP további adatok értékelését, 
számszerűsítését is biztosíthatja: 
• a tumor mértékének háromdimenziós meghatározását, 
• a daganat teljes heterogenitásának feltérképezését, 
• az infiltráció mélységének és mintázatának megrajzolását, 
• a cirkumferenciális reszekciós vonal pontos meghatározását, 
• valamennyi vaszkuláris és perineurális terjedés azonosítását, 
• a dysplasia és in situ carcinoma kiterjedésének kimutatását.  
Az OKP sajnos költség- és munkaigényesebb, mint a kimetszéses feldolgozás. Az 
anyagköltség háromszor, négyszer is meghaladja az eddigi kiadásokat. A patológus 




A cystectomiás preparátum szövettani feldolgozása során a makroblokkos technika 
alkalmazásának módszere – az orientált kivágási protokollal – lehetővé teszi a daganat 
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Accurate Determination of the Pathological Stage with the Gross 
Dissection Protocol for Radical Cystectomy (GDPRC) in Daily Routine 
Diagnostics 
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Abstract 
Purpose: The currently protocol for reporting urinary bladder cancer in radical 
cystectomies may exhibit limitations in the diagnostic accuracy, such as the risk for 
understaging, especially of cases in prostatic involvement. Difficulty exists in the 
verification of stage pT0 and assessment of surgical margins is suboptimal. Eliminate the 
potential compromises in sampling, we developed a daily practice gross dissection 
protocol where the radical cystectomies were totally embedded and evaluated 
histologically in whole-mount sections. 
Methods: Here were reported the first 138 consecutive specimens from 99 men and 39 
women from 2008 to the first quarter of 2012 inclusive; 9.2 macroblocks and 14 standard 
blocks were examined on overage. The incidence of cancer stages of our series was 
compared with the incidence of cancer stages, determined by retrieving the stage data of 
15586 radical cystectomies from the literature. The differences were analyzed with the 
one-sample z-test (p <0.05). 
Results: The following values were obtained (the first refers to our series): pT0 8.7% and 
6.1%; pTa 0.7% and 2.9%; pTis 2.9% and 6%; pT1 15.2% and 15.5%; pT2 21% and 
23.3%; pT3 34.8% and 34.3%; and pT4 16.7% and 11%. 
Conclusion: Our findings closely reflected the means of the published statistical data 
based on a large number of cases. The differences were due to the more detailed 
processing: the case numbers in groups pTis-pT2 were comparatively low, those in 
groups pT3-pT4 were higher. The difference found in group pT4 was significant. (p = 
0.0494) With this method only those samples were regarded as pT0 in which the 
granulomatous area and the haemosiderin deposition indicative of the earlier intervention 
were observable and the entire preparation was tumor-free. Although our protocol was 
three times more expensive than the currently used and the reporting time took four hours 
by identifying all features that can guide postoperative treatment has the monopoly of 
diagnostic accuracy.----------------------------------------- 
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